Grail Gets NY State Department of Health Approval for Galleri Multicancer Test

Grail said on Monday that its Galleri blood-based multicancer early detection test has been approved by the New York State Department of Health.

With the approval, the test may now be offered by prescription in New York state as a complement to existing single-cancer screening tests, the Menlo Park, California-based company said.

Galleri is designed to detect more than 50 cancer types through a routine blood draw and, when a cancer signal is detected, predict its origin. Grail launched the test in June in conjunction with the release of initial efficacy data from an ongoing prospective interventional study of the test.

Source: https://www.genomeweb.com/molecular-diagnostics/grail-gets-ny-state-department-health-approval-galleri-multicancer-test#.YUjI_7hKiUk